BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 33559714)

  • 21. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
    Sonomoto K; Yamaoka K; Kubo S; Hirata S; Fukuyo S; Maeshima K; Suzuki K; Saito K; Tanaka Y
    Rheumatology (Oxford); 2014 May; 53(5):914-8. PubMed ID: 24441153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anti-rheumatic effect of JAK-inhibitors].
    Yamaoka K; Maeshima K; Kubo S; Sonomoto K; Tanaka Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(2):112-7. PubMed ID: 22576568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
    Lee MY; Park SK; Park SY; Byun JH; Lee SM; Ko SK; Lee EK
    Clin Ther; 2015 Aug; 37(8):1662-76.e2. PubMed ID: 26243076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
    Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
    Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tofacitinib for treatment of rheumatoid arthritis.
    Rakieh C; Conaghan PG
    Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
    Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
    Charles-Schoeman C; Wicker P; Gonzalez-Gay MA; Boy M; Zuckerman A; Soma K; Geier J; Kwok K; Riese R
    Semin Arthritis Rheum; 2016 Dec; 46(3):261-271. PubMed ID: 27443588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
    Burgos-Vargas R; Cardiel M; Xibillé D; Pacheco-Tena C; Pascual-Ramos V; Abud-Mendoza C; Mahgoub E; Rahman M; Fan H; Rojo R; García E; Santana K
    Reumatol Clin (Engl Ed); 2019; 15(1):43-53. PubMed ID: 28552437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study.
    Di Muzio C; Di Cola I; Shariat Panahi A; Ursini F; Iagnocco A; Giacomelli R; Cipriani P; Ruscitti P
    Arthritis Res Ther; 2024 Jan; 26(1):14. PubMed ID: 38178250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis.
    Chen YM; Chen HH; Huang WN; Liao TL; Chen JP; Chao WC; Lin CT; Hung WT; Hsieh CW; Hsieh TY; Chen YH; Chen DY
    PLoS One; 2017; 12(11):e0188454. PubMed ID: 29155868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
    van der Heijde D; Strand V; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
    Arthritis Rheumatol; 2019 Jun; 71(6):878-891. PubMed ID: 30666826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.
    Migita K; Izumi Y; Jiuchi Y; Kozuru H; Kawahara C; Izumi M; Sakai T; Nakamura M; Motokawa S; Nakamura T; Kawakami A
    Clin Exp Immunol; 2014 Feb; 175(2):208-14. PubMed ID: 24665995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.
    Charles-Schoeman C; Fleischmann R; Davignon J; Schwartz H; Turner SM; Beysen C; Milad M; Hellerstein MK; Luo Z; Kaplan IV; Riese R; Zuckerman A; McInnes IB
    Arthritis Rheumatol; 2015 Mar; 67(3):616-25. PubMed ID: 25470338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
    Tanaka Y; Yamaoka K
    Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
    Pérez-Román DI; Ortiz-Haro AB; Ruiz-Medrano E; Contreras-Yáñez I; Pascual-Ramos V
    Rheumatol Int; 2018 Apr; 38(4):599-606. PubMed ID: 29264637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.
    Xu S; Wang Y; Lu J; Xu J
    Rheumatol Int; 2012 Nov; 32(11):3397-403. PubMed ID: 22057136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis.
    Li Y; Yuan L; Yang J; Lei Y; Zhang H; Xia L; Shen H; Lu J
    Mediators Inflamm; 2019; 2019():5617431. PubMed ID: 31780862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
    Tanaka Y; Maeshima K; Yamaoka K
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
    Gupta AK; Cernea M; Lynde CW
    Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.